Company Description
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes.
The company was founded in 2004 and is headquartered in Durham, North Carolina.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 185 |
| CEO | Laura Niklason |
Contact Details
Address: 2525 East North Carolina Highway 54 Durham, North Carolina 27713 United States | |
| Phone | 919 313 9633 |
| Website | humacyte.com |
Stock Details
| Ticker Symbol | HUMA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001818382 |
| CUSIP Number | 44486Q103 |
| ISIN Number | US44486Q1031 |
| Employer ID | 85-1763759 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Laura E. Niklason M.D., Ph.D. | Founder, President, Chief Executive Officer and Director |
| Dale A. Sander | Chief Financial Officer, Chief Corporate Development Officer and Treasurer |
| Dr. Heather Ledbetter Prichard Ph.D. | Chief Operating Officer |
| Sabrina Osborne GPHR, SPHR | Chief People Officer |
| William John Scheessele | Chief Commercial Officer |
| Dr. Shamik J. Parikh M.D. | Chief Medical Officer |
| Harold Alterson | Chief Quality Officer |
| Dr. Yang Cao M.D., Ph.D. | Chief Regulatory Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 20, 2024 | 144 | Filing |
| Nov 19, 2024 | 144 | Filing |
| Nov 18, 2024 | 144 | Filing |
| Nov 18, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 424B3 | Prospectus |
| Nov 8, 2024 | 10-Q | Quarterly Report |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | 8-K | Current Report |